To systematically evaluate the clinical efficacy of qi-benefiting and blood-activating therapy in the treatment of recurrent angina pectoris after percutaneous coronary intervention(PCI) for coronary heart disease.Methods:CNKI，CSPD，CCD，CBM，PubMed，and Web of Science were searched for randomized controlled trials(RCTs) on qi-benefiting and blood-activating therapy in the treatment of recurrent angina pectoris after PCI for coronary heart disease from database inception to December 2021.The Cochrane risk-of-bias tool and the modified Jadad scale were used to evaluate the quality of the included studies.Meta-analysis was performed using RevMan 5.3 and Stata16.0 software.Results:Twenty RCTs were included，with 1 412 patients involved.The results of Meta-analysis showed that compared with western medicine alone，qi-benefiting and blood-activating therapy combined with western medicine could significantly improve the clinical total effective rate(OR=3.60，95%CI 2.14 to 6.04，P<0.000 01)，efficacy on angina pectoris(OR=4.25，95%CI 2.79 to 6.45，P<0.000 01)，traditional Chinese medicine(TCM) syndrome efficacy(OR=4.38，95%CI 2.97 to 6.45，P<0.000 01)，and ECG efficacy(OR=2.47，95%CI 1.56 to 3.90，P=0.000 1)，and reduce the number of angina attacks(MD＝-0.39，95%CI -0.75 to -0.02，P=0.04)，total cholesterol(MD＝-0.35，95%CI -0.55 to -0.15，P=0.000 6)，low-density lipoprotein cholesterin(MD＝-0.37，95%CI -0.53 to -0.21，P<0.000 01)，high-sensitivity C-reactive protein(MD＝-1.41，95%CI -2.05 to -0.76，P<0.000 1)，and left ventricular ejection fraction(LVEF)(OR=1.47，95%CI 0.54 to 2.40，P=0.002).However，the improvement of TCM syndrome score(MD＝-2.43，95%CI -5.83 to 0.96，P=0.16) and angina attack duration(MD＝-0.44，95%CI -1.18 to 0.30，P=0.24) showed no significant difference compared with the control group.Conclusion:The qi-benefiting and blood-activating therapy can further improve the clinical efficacy of patients with recurrent angina pectoris after PCI for coronary heart disease with good safety.